AI assistant
CANN GROUP LIMITED — Board/Management Information 2023
Dec 3, 2023
64603_rns_2023-12-03_28ea3642-a468-45b9-be83-de797b1744ec.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Not for distribution or release in the United States
==> picture [114 x 53] intentionally omitted <==
ASX ANNOUNCEMENT
Resignation of Chief Financial Officer/ Company Secretary
4 December 2023 – Cann Group Limited (ASX:CAN) advises that its Chief Financial Officer (CFO) & Company Secretary, Deborah Ambrosini, has resigned for personal reasons effective 22[nd] of December.
Chief Executive Officer of Cann, Peter Koetsier, said: “Deborah has made an outstanding contribution to Cann having served as the Group’s CFO for more than 2 years and Company Secretary for the past year. She leaves a strong legacy and we wish her well in the future.” The Cann Board also thanks Deborah for her contribution over what has been a transformative period for the Company.
Cann will initiate a process to appoint a new CFO.
Steven Notaro, Head of Legal and Regulatory Affairs, will assume responsibilities as Company Secretary effective immediately,
Authorised for release by the Board of Directors, Cann Group Limited.
For all media enquiries please contact:
Jackson Paine Corporate Communications Manager +61 439 492 955 [email protected]
For all other information please contact:
Peter Koetsier Steven Notaro CEO Company Secretary Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.
Learn more at: www.canngrouplimited.com | www.satipharm.com
Cann Group Limited ACN 25 603 949 739, Australia 262-276 Lorimer Street, Port Melbourne 3207, Victoria, Australia Tel +61 (0) 3 9095 7088 | www.canngrouplimited.com